Advertisement

PET Tracers for Brain Imaging

  • Christine TangEmail author
  • Vincenzo Militano
Chapter
Part of the Clinicians’ Guides to Radionuclide Hybrid Imaging book series (CGRHI)

Abstract

Positron emission tomography (PET) is an imaging technology developed to use compounds radiolabelled with positron emitting radioisotopes to image biochemical and molecular properties in vivo. The use of molecular imaging include diagnosing the biological nature of disease and assessment of therapies [1]. 2-[18F]Fluoro-2-deoxyglucose (FDG) is the most widely available tracer used in PET neuroimaging to image cerebral metabolism of glucose.

References

  1. 1.
    Phelps ME. Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci U S A. 2000;97:9226–33.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Kato T, Inui Y, Nakamura A, Ito K. Brain fluorodeoxyglucose (FDG) PET in dementia. Ageing Res Rev. 2016;30:73–84.PubMedGoogle Scholar
  3. 3.
    Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–19.Google Scholar
  4. 4.
    Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013;54:70–7.PubMedGoogle Scholar
  5. 5.
    George N, Gean E, Nandi A, Brašić JR, Wong DF. Radiotracers used to image the brains of patients with Alzheimer’s disease. In: Imaging of the human brain in health and disease. Amsterdam: Elsevier; 2014. p. 407–16.Google Scholar
  6. 6.
    Cselényi Z, Jönhagen ME, Forsberg A, Halldin C, Julin P, Schou M, et al. Clinical validation of 18F-AZD4694, an amyloid-β-specific PET radioligand. J Nucl Med. 2012;53:415–24.PubMedGoogle Scholar
  7. 7.
    Politis M, Pagano G, Niccolini F. Imaging in Parkinson’s disease. Int Rev Neurobiol. 2017;132:233–74.PubMedGoogle Scholar
  8. 8.
    Pavese N, Brooks DJ. Imaging neurodegeneration in Parkinson’s disease. Biochim Biophys Acta Mol basis Dis. 2009;1792:722–9.Google Scholar
  9. 9.
    Dupont AC, Guilloteau D, Kassiou M, Ribeiro MJ, Vercouillie J, Katsifis A, et al. Radiopharmaceuticals for PET imaging of neuroinflammation. Med Nucl. 2016;40:72–81.Google Scholar
  10. 10.
    Cerami C, Iaccarino L, Perani D. Molecular imaging of neuroinflammation in neurodegenerative dementias: the role of in vivo PET imaging. Int J Mol Sci. 2017;18:993.PubMedCentralGoogle Scholar
  11. 11.
    Dupont A-C, Largeau B, Santiago Ribeiro M, Guilloteau D, Tronel C, Arlicot N. Translocator protein-18 kDa (TSPO) positron emission tomography (PET) imaging and its clinical impact in neurodegenerative diseases. Int J Mol Sci. 2017;18:785.PubMedCentralGoogle Scholar
  12. 12.
    Ghadery C, Koshimori Y, Coakeley S, Harris M, Rusjan P, Kim J, et al. Microglial activation in Parkinson’s disease using [18F]-FEPPA. J Neuroinflammation. 2017;14:8.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Kreisl WC, Lyoo CH, Liow J-S, Wei M, Snow J, Page E, et al. (11)C-PBR28 binding to translocator protein increases with progression of Alzheimer’s disease. Neurobiol Aging. 2016;44:53–61.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Herholz K. Brain tumors: an update on clinical PET research in gliomas. Semin Nucl Med. 2017;47:5–17.PubMedGoogle Scholar
  15. 15.
    Basu S, Alavi A. Molecular imaging (PET) of brain tumors. Neuroimaging Clin N Am. 2009;19:625–46.PubMedGoogle Scholar
  16. 16.
    Gulyás B, Halldin C. New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Q J Nucl Med Mol Imaging. 2012;56:173–90.PubMedGoogle Scholar
  17. 17.
    Juhász C, Dwivedi S, Kamson DO, Michelhaugh SK, Mittal S. Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors. Mol Imaging. 2014;13  https://doi.org/10.2310/7290.2014.00015.Google Scholar
  18. 18.
    Shields AF, Grierson JR, Dohmen BM, Machulla H-J, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334–6.PubMedGoogle Scholar
  19. 19.
    Borbely K, Wintermark M, Martos J, Fedorcsak I, Bognar L, Kasler M. The pre-requisite of a second-generation glioma PET biomarker. J Neurol Sci. 2010;298:11–6.PubMedGoogle Scholar
  20. 20.
    Zimmer L, Luxen A. PET radiotracers for molecular imaging in the brain: past, present and future. Neuroimage. 2012;61:363–70.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Institute of Nuclear MedicineUniversity College of London HospitalLondonUK

Personalised recommendations